Pancreatic Cancer

Results from the phase 3 NAPOLI trial show survival benefits for patients with metastatic pancreatic ductal adenocarcinoma treated with Onivyde plus oxaliplatin, leucovorin and fluorouracil.

Researchers have found alternatives to opioid pills, which reduces the risk of misuse and addiction in patients undergoing pancreatic cancer surgery.

As majority leader Steve Scalise announces his new cancer diagnosis and author Ibram X. Kendi reveals that he is cancer free, this is what’s happening in the oncology space this week.

Most of us dread, simply dread, hearing the words, “I’m sorry you have cancer.” I did.

Staging a laparoscopy can help patients with pancreatic cancer identify the stage of cancer, where it spread and what the best treatment may be, a recent study shows.

I remember my first trip to the “chemo room”.

From country music star, Toby Keith, providing an update on his cancer to the Duchess of York announcing her diagnosis, here’s what’s happening in the oncology space this week.

From actress and journalist Maria Menounos opening up about her pancreatic diagnosis to the Pennsylvania governor signing a bill for free screenings, here’s what’s happening in the oncology space this week.

From talk show host Jerry Springer’s death to “The Young and the Restless” star announcing a cancer diagnosis, here is what’s happening in the oncology space this week.

The COVALENT-102 trial will investigate BMF-219 in patients with non-small cell lung cancer, colorectal and pancreatic cancers.

Surviving cancer was tougher than my hardest days in the military. Here are some things I learned along the way.

The targeted therapy appeared to be safe and effective in treating patients with KRAS G12C mutated pancreatic cancer, according to results from a recent study.

The combination of pelareorep, Tecentriq, gemcitabine and Abraxane was granted FDA fast-track designation after demonstrating a 69% objective response rate in patients with advanced/metastatic pancreatic ductal adenocarcinoma.

Cancer made me realize that there is more to life than just work.

From “Star Trek” actors supporting the Pancreatic Cancer Action Network to Michelle Obama meeting with a sarcoma survivor and an update on Jane Fonda’s cancer, here’s what’s happening in the cancer space this week.

As a pancreatic cancer survivor, I realized how important it is to help others who are in the throes of their cancer experience.

From the death of “Schitt’s Creek” Emmy winning-producer “Ben Feigin” to “Good Charlotte” signer Joel Madden donating nearly $200,000 to an osteosarcoma nonprofit, here’s what’s happening in the cancer space this week.

The novel drug PY159 will be studied as a single agent and in combination with Keytruda for patients with certain solid tumors — including ovarian, pancreatic, lung, head and neck, colorectal and breast cancers.

Receiving a pancreatic cancer diagnosis has caused me to reexamine my spirituality, which led me to believe that my life is a line, rather than a single dot in time.

Treatment with FOLFIRINOX, a combination of several chemotherapy agents, prior to the surgical resection of pancreatic cancer increased survival outcomes when compared to historical data.

The first patient enrolled onto a phase 1 trial has received TCMB07, an investigational drug, for the treatment of cachexia, a severe disorder that may occur in more than half of patients with advanced-stage cancer.

The use of a chemotherapy-free, combination regimen as a maintenance treatment option was associated with an improvement in survival in a group of patients with advanced pancreatic cancer.

According to the manufacturer, this is the first-in-human clinical trial of Allocetra combined with chemotherapy in patients with peritoneal metastases arising from solid cancers.

The addition of nimotuzumab to a treatment regimen of the chemotherapy gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer.

As I go in for another cancer follow-up, I need to remind myself that what could happen is different from what would happen.